2020
DOI: 10.1001/jama.2019.22238
|View full text |Cite
|
Sign up to set email alerts
|

Informed Consent for Stem Cell–Based Interventions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 7 publications
0
2
0
Order By: Relevance
“…147 Benefits should be described accurately and not overemphasized, particularly in light of misinformation surrounding "stem-cell therapies" that may heighten patient expectations such that patients may not give adequate consideration to other treatment options. 137,[148][149][150][151][152][153][154] The patient should be informed that regenerative medicine interventions are not currently considered standard of care. The FDA approval status of the intervention being proposed should be provided, and if the intervention is being offered as part of a research protocol, the internal review board status of the research study should be discussed.…”
Section: Informed Consentmentioning
confidence: 99%
See 1 more Smart Citation
“…147 Benefits should be described accurately and not overemphasized, particularly in light of misinformation surrounding "stem-cell therapies" that may heighten patient expectations such that patients may not give adequate consideration to other treatment options. 137,[148][149][150][151][152][153][154] The patient should be informed that regenerative medicine interventions are not currently considered standard of care. The FDA approval status of the intervention being proposed should be provided, and if the intervention is being offered as part of a research protocol, the internal review board status of the research study should be discussed.…”
Section: Informed Consentmentioning
confidence: 99%
“…147 Benefits should be described accurately and not overemphasized, particularly in light of misinformation surrounding “stem-cell therapies” that may heighten patient expectations such that patients may not give adequate consideration to other treatment options. 137,148–154…”
Section: Introducing Regenerative Medicine Into Clinical Practicementioning
confidence: 99%
“…Given genetic information's personal and sensitive nature, patients must be fully informed about the purpose, risks, and potential implications of genetic testing before they decide to undergo such testing. The complexity of genomic data and the potential for incidental findings require a comprehensive and understandable disclosure process (Master, Smith, & Tilburt, 2020;Miao, Zhang, Yi, & Huang, 2020). Healthcare professionals, including pharmacists, play a crucial role in ensuring that patients comprehend the nuances of pharmacogenomic testing.…”
Section: Ethical and Legal Considerations In Pharmacogenomicsmentioning
confidence: 99%